Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG3970 in Active Primary Sjögren's Syndrome
NCT04700280Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of GLPG3970 in primary Sjögren's syndrome, sponsored by Galapagos NV. Started Jan 2021; status: terminated.
02
Drugs
GLPG3970
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NCT04700280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700280.